| 李真真,韩 宇.靶向HER3逆转EGFR抑制剂耐药机制的研究进展[J].中国肿瘤,2016,25(6):442-447. |
| 靶向HER3逆转EGFR抑制剂耐药机制的研究进展 |
| Research Progress in Targeting HER3 Receptors to Overcome Resistance of EGFR Inhibitor in Cancer |
| 投稿时间：2015-08-31 |
| DOI：10.11735/j.issn.1004-0242.2016.06.A009 |
|
 |
| 中文关键词: HER3 EGFR抑制剂 耐药机制 逆转 |
| 英文关键词:HER3 EGFR inhibitors resistance mechanism reverse |
| 基金项目:国家青年科学基金项目（81101798）；黑龙江省青年科学基金项目（QC2010115） |
|
| 摘要点击次数: 2088 |
| 全文下载次数: 1197 |
| 中文摘要: |
| 摘 要：表皮生长因子受体家族，又称HER/ERBB家族，由四个成员组成：HER1/EGFR/ERBB1、HER2/NEU/ERBB2、HER3/ERBB3和HER4/ERBB4，在肿瘤的发生发展中具有重要作用。以EGFR家族为靶点的治疗已经成为当前的研究热点，尤以HER1、HER2的研究最为深入，相应的靶向治疗药物已应用于临床。但随着时间的推移，EGFR抑制剂耐药现象逐渐出现。目前研究发现，针对HER3的靶向治疗策略可能逆转这种耐药现象。全文综述HER3在肿瘤发生发展中的角色，EGFR抑制剂耐药机制以及HER3抗体逆转EGFR抑制剂耐药的研究进展，以期为优化EGFR家族靶向治疗提供新的思路。 |
| 英文摘要: |
| Abstract：Epidermal growth factor receptor family，also known as the HER/ERBB family，consists of four members namely HER1/EGFR/ERBB1，HER2/NEU/ERBB2，HER3/ERBB3 and HER4/ERBB4，which play important roles in the development of cancer. Drugs targeting EGFR family have already been the current research hotspot. Of these，HER1 and HER2 are the most extensively studied，and corresponding target drugs have been implicated in clinic. But with the passage of time，many patients gradually appeared resistance to EGFR inhibitors. To date，it is believed that targeting HER3 may overcome therapeutic resistance. In this review，we focus on the role of HER3 in the development of cancer and mechanisms of resistance to EGFR inhibitors，discuss the latest advances in therapeutic strategies targeting HER3 to overcome the resistance phenomenon. We hope to provide a new perspective for in-depth analysis of targeting EGFR family. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |